Evaluation of a participant centred type 2 diabetes group education program (#359)
Australian Diabetes Council has been conducting Medicare funded type 2 group education programs (T2GEP) since 2008. The T2GEP was revamped in April 2011 to incorporate a more participant centred approach. The eight session program, underpinned by three theoretical models and practical learning was conducted by a multidisciplinary health professional team.
The program aimed to improve participant’s knowledge, psychosocial adjustment, self care behaviours and clinical outcomes. Outcomes were measured pre, immediately, 2, 5 and 11 months after the program applying validated tools ie Diabetes Knowledge Questionnaire (DKQ), Problem Area In Diabetes (PAID) scale, Summary of Diabetes Self Care Activity scale adapted for the Australian context (SDSCA-AUS) and point of care instruments for HbA1c, total and HDL cholesterol.
Statistical analysis was conducted using SPSSInc, PASWStatistics18
Preliminary analysis (n=41) indicate statistically significant improvements in DKQ scores (67.6% SD±17% before to 81.5% SD±19% correct answers immediately after; p<0.001); and was maintained at 76.3% SD±13% at two months follow-up. Mean adjusted PAID scores improved statistically significant (18.9 pre to 13.6 two month after; p<0.0006). At two months follow-up improvements were identified in self care behaviours: frequency of eating high fat foods and checking feet. Mean HbA1c was maintained from 6.76% SD±0.92 pre to 6.79% SD±0.95 (NS) at two months; mean BMI decreased from 30.74 to 30.30 (p<0.02); mean total cholesterol improved from 3.99 mmol/L SD±0.92 to 3.74 mmol/L SD±0.75 (p<0.002), HDL cholesterol improved from 1.05mmol/L to 1.02mmol/L (NS); mean systolic (137.0 to 137.2 mmHg - NS) and diastolic (76.0 to 74.2 mmHg - NS) Blood Pressure was maintained at two months follow up.
Preliminary results show positive effects of the program on participant’s knowledge, psychosocial adjustment and some clinical indicators.
Full analysis of 125 participants will be presented for pre, immediately after, 2, 5 and 11 months follow up; adjusted for medication, age, and duration of diabetes where possible.